Akademik Veri Yönetim Sistemi
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2026 (SCI-Expanded, Scopus)
Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma primarily affecting older adults, and its optimal treatment strategy remains controversial. This study evaluated treatment responses, survival outcomes, and prognostic factors in patients with MCL. Medical records of patients diagnosed with MCL between 1999 and 2020 were retrospectively analyzed. Demographic characteristics, laboratory findings, treatment regimens, progression-free survival (PFS), overall survival (OS), and potential prognostic factors were assessed. Seventy-five patients were included (median age 63.1 +/- 11.3 years; 77% male). Advanced-stage disease was present in 94.7%. The median OS was 48.9 +/- 41.6 months. Longer OS was associated with younger age, low Mantle Cell Lymphoma International Prognostic Index (MIPI) and MIPI-c scores, low Ki-67, and absence of disease progression within 24 months (POD24) (p = 0.042, p = 0.009, p = 0.010, p = 0.004, p = 0.024, respectively). Autologous stem cell transplantation (ASCT) and maintenance rituximab were also linked to improved OS (p < 0.001, p = 0.046). In multivariate Cox regression, higher Ki-67 independently increased mortality risk (HR = 1.064 per 1% increase), while the absence of ASCT markedly elevated risk (HR = 34.832; chi & sup2; = 79.01, df = 5, p < 0.001). Our findings underscore the prognostic value of risk scores in predicting OS and highlight Ki-67 as an independent risk factor. Furthermore, the positive impact of ASCT on OS emphasizes the importance of considering ASCT in eligible patients.